Our Technology
Predictive Precision Powered by AI: The CTR Platform
CTR Report is built on Scipher Medicine’s advanced network biology and AI-driven R&D, leveraging the company’s proprietary Spectra platform. Developed through years of rigorous research and validated across multiple disease areas, CTR Report integrates the industry’s most comprehensive protein interaction network model with genotype, phenotype and treatment modules to accurately predict the likelihood of failure for drug targets—before costly trials or next trial phases begin.
Clinical Trial Ranking Report
The Prediction Engine for Clinical Research
SPECTRA Rx Platform is AI Enabled to Predict The Most Highly Efficacious Drug Targets
Mapping the Complexity of Disease
Clinical Trial Ranking Report (CTR Report) analyzes the industry’s most complete and validated network of protein-protein interactions in human cells, providing a systems-level view of disease biology and therapeutic opportunity.
Relevance of Targets to Disease Modules
Pinpointing Disease Drivers
Our platform identifies three key modules for each disease:- •
Treatment Module
(proteins shown to revert disease expression patterns) - •
Phenotype Module
(genes differentially expressed in disease tissue) - • Genotype Module
(genes genetically linked to the disease)
Target Ranking Algorithm
CTR Reports Target Ranking: Prioritizing What Matters.
The Pathway Enrichment analysis identifies the pathways enriched among the targets of approved drugs for the selected disease. Each bar indicates how many approved drug targets are associated with the respective pathway. Pathways in which the selected target is also enriched are highlighted, illustrating the degree of overlap with the pathways of approved drug targets.
Real-World Validation
Proven Predictive Power
Comprehensive retrospective analysis confirms that poorly ranked targets always fail. Some representative disease areas illustrate the predictive power of this ranking methodology: Alzheimer’s, Parkinson’s, and ALS drug development.Clinical Trial Ranking Report is Available as a Subscription Service For Life Sciences and Investors
Actionable Insights for Stakeholders
Empowering Biopharma, Investors, and Researchers
Our Clinical Trial Rank Report can rapidly identify bad targets, helping prioritize high-probability assets, refine portfolios, and reduce wasted investment—enabling confident, data-driven go/no-go decisions.Investors
• Increase returns by avoiding new/continued investments in assets with high probability of failure.
• Incorporate clinical trial rankings in public company trading analysis.
Life Sciences
• Early target ranking for program investment decisions.
• Portfolio reviews
• Indication expansion analysis (targets can be evaluated across indications).